

Megan C Roberts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8824917/publications.pdf>

Version: 2024-02-01

33
papers

864
citations

759233

12
h-index

526287

27
g-index

34
all docs

34
docs citations

34
times ranked

1457
citing authors

#	ARTICLE	IF	CITATIONS
1	Multifactorial causal beliefs and colorectal cancer screening: A structural equation modeling investigation. <i>Journal of Health Psychology</i> , 2022, 27, 2463-2477.	2.3	4
2	Examining the role of language competency in genetic testing awareness among adults in the United States. <i>Journal of Genetic Counseling</i> , 2022, , .	1.6	0
3	The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation. <i>Journal of Personalized Medicine</i> , 2022, 12, 692.	2.5	11
4	Involving patients and their families in deciding to use next generation sequencing: Results from a nationally representative survey of U.S. oncologists. <i>Patient Education and Counseling</i> , 2021, 104, 33-39.	2.2	2
5	Complementary approaches to problem solving in healthcare and public health: implementation science and human-centered design. <i>Translational Behavioral Medicine</i> , 2021, 11, 1115-1121.	2.4	42
6	Age at initiation of screening mammography by family history of breast cancer in the breast cancer surveillance consortium. <i>Cancer Causes and Control</i> , 2021, 32, 103-107.	1.8	6
7	Patient Perspectives on the Risk-Based NLST Outcomes Tool for Lung Cancer Screening. <i>Journal of Cancer Education</i> , 2021, , 1.	1.3	2
8	Improving reporting standards for polygenic scores in risk prediction studies. <i>Nature</i> , 2021, 591, 211-219.	27.8	265
9	Predictors of Chronic Opioid Use: A Population-Level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1581-1589.	6.3	2
10	Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey. <i>JCO Precision Oncology</i> , 2021, 5, 701-709.	3.0	6
11	Advancing precision public health using human genomics: examples from the field and future research opportunities. <i>Genome Medicine</i> , 2021, 13, 97.	8.2	26
12	Ethiopian paediatric oncology registry progress report: documentation practice improvements at tertiary care centre in Addis Ababa, Ethiopia. <i>Archives of Disease in Childhood</i> , 2021, 106, 1244-1245.	1.9	1
13	Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network. <i>Journal of Personalized Medicine</i> , 2021, 11, 647.	2.5	13
14	Uptake of Genetic Testing Among Patients with Cancer At Risk for Lynch Syndrome in the National Health Interview Survey. <i>Cancer Prevention Research</i> , 2021, 14, 927-932.	1.5	6
15	Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. <i>Pharmacogenomics</i> , 2021, 22, 1121-1133.	1.3	5
16	Results of a pre-implementation analysis of Ethiopiaâ€™s National Pediatric Cancer Registry. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1940-1947.	0.9	3
17	Communication About Hereditary Cancers on Social Media: A Content Analysis of Tweets About Hereditary Breast and Ovarian Cancer and Lynch Syndrome. <i>Journal of Cancer Education</i> , 2020, 35, 131-137.	1.3	9
18	Barriers and facilitators for cascade testing in genetic conditions: a systematic review. <i>European Journal of Human Genetics</i> , 2020, 28, 1631-1644.	2.8	55

#	ARTICLE	IF	CITATIONS
19	Stakeholder Perspectives on Overcoming Barriers to Cascade Testing in Lynch Syndrome: A Qualitative Study. <i>Cancer Prevention Research</i> , 2020, 13, 1037-1046.	1.5	12
20	Early career investigators and precision public health. <i>Lancet, The</i> , 2019, 394, 382-383.	13.7	6
21	Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey. <i>Journal of Personalized Medicine</i> , 2019, 9, 26.	2.5	21
22	Leveraging Implementation Science to Address Health Disparities in Genomic Medicine: Examples from the Field. <i>Ethnicity and Disease</i> , 2019, 29, 187-192.	2.3	43
23	Psychosocial, attitudinal, and demographic correlates of cancer-related germline genetic testing in the 2017 Health Information National Trends Survey. <i>Journal of Community Genetics</i> , 2019, 10, 453-459.	1.2	8
24	The FDA authorization of direct-to-consumer genetic testing for three BRCA1/2 pathogenic variants: a twitter analysis of the public's response. <i>JAMIA Open</i> , 2019, 2, 411-415.	2.0	8
25	Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 719-726.	2.5	5
26	Engagement with Genetic Information and Uptake of Genetic Testing: the Role of Trust and Personal Cancer History. <i>Journal of Cancer Education</i> , 2018, 33, 893-900.	1.3	15
27	Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature. <i>Health Affairs</i> , 2018, 37, 801-808.	5.2	114
28	Twitter use at the 2016 Conference on the Science of Dissemination and Implementation in Health: analyzing #DIScience16. <i>Implementation Science</i> , 2018, 13, 34.	6.9	22
29	Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 303-310.	2.5	80
30	The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use. <i>Journal of Community Genetics</i> , 2017, 8, 141-146.	1.2	39
31	Patient-Centered Communication for Discussing Oncotype DX Testing. <i>Cancer Investigation</i> , 2016, 34, 205-212.	1.3	5
32	Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers. <i>Journal of Oncology Practice</i> , 2015, 11, 273-277.	2.5	17
33	Barriers and Facilitators for Population Genetic Screening in Healthy Populations: A Systematic Review. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	10